Benefits PRINT PAGE
Overview
Technology Description
Implementation
Benefits

Benefits

The IV™flow offers the following benefits:

Safety:

  • During clinical trials it was proven that the IV™flow reduces adverse events by 55% (statistically significant, p-value of 0.0069)
    (Ref. SATRGAIT Trial, (Data on file Varori))
  • Less intervention with the infusion set reduces non-communal infections;
  • The automatic shut-down means that iatrogenically induced air embolisms are virtually eliminated and that the back-flow of blood is reduced;
  • A wider range of therapies (drugs with a short half-life) can be administered with gravity infusion sets; and
  • Constant flow rate reduces the chances of pulmonary congestion, hyponatremia and over– or under-hydration.

Efficiency:

  • During clinical trials it was proven that the mean deviation from the intended flow rate (where the IV™flow was incorporated) was just more than 5ml/hour compared to a mean deviation from the intended flow rate (where the IV™flow was NOT incorporated) of more than 30ml/hour (statistically significant, p-value of 0.00818)
    (Ref. SATRGAIT Trial, (Data on file Varori))
  • Constant flow rate means correct therapeutic concentration of the therapy administered which leads to higher efficiency of the therapy;
  • With virtually no risk of air embolisms, fluid containers can run empty with no wastage; and
  • Studies have shown a substantial and potential time saving of clinical staff’s time spent managing infusion sets.

Management:

  • Constant hydrostatic pressure means constant flow rate and no or little recalibration;
  • Due to the shutoff mechanism, no repriming is necessary once the fluid containers run empty or need to be replaced; and
  • Once stabilised, the IV™flow will operate on its own and will save valuable management time.

Compatibility:

  • It may be used to administer all kinds of fluids (colloids, crystalloids, packed cells, TPN, whole blood and oncotherapy;
  • It can be used in conjunction with any gravity based infusion, transfusion or oncology set, as well as with volumetric infusion pumps*; and
  • The IV™flow can be used with any type of fluid container, be it rigid, semi-rigid or collapsible.

Cost:

  • During clinical trials it was proven that the IV™flow reduces costs related to adverse events by 76% (statistically significant, p-value of 0.0069)
    (Ref. SATRGAIT Trial, (Data on file Varori))
  • International studies have shown that the majority of adverse events associated with gravity infusion can be prevented by the IV™flow with savings in valuable management time, consumables and wastage;
  • It is a disposable device with no maintenance required;
  • It is packed and sterilised with the current infusion sets;
  • Training is easy as virtually no current protocols are changed; and
  • Manageability and compatibility can lead to stock standardisation.

* Tests are currently being conducted for the IV™flow’s compatibility with blood products / TPN as well as with volumetric infusion pumps. The results are expected and will be made available in October 2004.